Table 2 Uni- and multivariate Cox-regression analysis for the prediction of progression-free and overall survival.

PFS	univariate Cox-regression		multivariate Cox-regression
Parameter	p value	Hazard-ratio (95% CI)	p value	Hazard-ratio (95% CI)
sLAG3 baseline	0.003	1.006 (1.002–1.011)	0.039	1.005 (1.000–1.009)
Age	0.761	1.004 (0.979–1.030)
Sex	0.599	0.877 (0.538–1.430)
UICC tumor stage	0.263	1.940 (0.608–6.193)
Tumor entity	<0.001	1.333 (1.160–1.532)	<0.001	1.310 (1.134–1.513)
Prior therapy	0.234	1.395 (0.806–2.416)
ICI regimen	0.594	0.924 (0.691–1.235)
ECOG PS	0.253	1.257 (0.849–1.861)
Leukocyte count	0.264	1.033 (0.976–1.094)
Sodium	0.107	0.947 (0.887–1.012)	0.164	0.949 (0.881–1.022)
Potassium	0.354	0.805 (0.509–1.273)
ALT	0.179	1.004 (0.998–1.011)
AST	0.270	1.005 (0.996–1.013)
Bilirubin	0.101	1.527 (0.920–2.535)	0.451	1.213 (0.734–2.007)
Creatinine	0.814	0.814 (0.781–1.370)
LDH	0.777	1.000 (0.998–1.002)

OS	univariate Cox-regression		multivariate Cox-regression
Parameter	p value	Hazard-ratio (95% CI)	p value	Hazard-ratio (95% CI)
sLAG3 baseline	0.039	1.004 (1.000–1.009)	0.015	1.006 (1.001–1.011)
Age	0.679	1.006 (0.979–1.033)
Sex	0.877	0.871 (0.507–1.498)
UICC tumor stage	0.450	1.726 (0.418–7.125)
Tumor entity	<0.001	1.328 (1.138–1.550)	0.038	1.195 (1.010–1.414)
Prior therapy	0.363	1.325 (0.723–2.428)
ICI regimen	0.553	0.907 (0.658–1.252)
ECOG PS	0.030	1.613 (1.049–2.482)	0.002	2.119 (1.321–3.401)
Leukocyte count	0.184	1.038 (0.982–1.097)
Sodium	0.133	0.953 (0.894–1.015)
Potassium	0.837	0.946 (0.558–1.604)
ALT	0.011	1.011 (1.002–1.019)	0.046	1.017 (1.000–1.033)
AST	0.055	1.010 (1.000–1.021)	0.864	0.997 (0.979–1.018)
Bilirubin	0.147	1.510 (0.865–2.635)
Creatinine	0.449	0.852 (0.562–1.291)
LDH	0.924	1.000 (0.998–1.002)

sLAG3 soluble lymphocyte activation gene-3, UICC Union for International Cancer Control, AST aspartate transaminase, BMI body-mass-index, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase

Search